Copyright
©The Author(s) 2025.
World J Gastrointest Pharmacol Ther. Dec 5, 2025; 16(4): 109177
Published online Dec 5, 2025. doi: 10.4292/wjgpt.v16.i4.109177
Published online Dec 5, 2025. doi: 10.4292/wjgpt.v16.i4.109177
Table 1 Effects of postbiotics on various liver disorders
| Ref. | Type of the study | Postbiotic involved | Mechanisms and outcomes |
| Inactivated bacteria | |||
| Depommier et al[29] | In vivo in mice | A. muciniphila | Increased energy expenditure, obesity |
| Depommier et al[30] | Clinical trial | A. muciniphila | Improves obesity with insulin resistance |
| Andresen et al[31] | Clinical trial | Bifidobacterium bifidum | Improves symptoms of irritable bowel syndrome |
| Shin et al[32] | In vivo: Male rats | B. longum SPM1207 | Decreases total and low-density lipoprotein cholesterol |
| Martorell et al[33] | In vivo: Caenorhabditis elegans. In vitro: Human colonic epithelial cells | B. longum CECT 7347 | Alleviate gut barrier disruption by its anti-inflammatory properties |
| Nakamura et al[34] | In vivo: Male c57BL/6n mice | Lactobacillus amylovorus CP 1563 | Treatment and prevention of dyslipidemia |
| Aiba et al[35] | In vitro | Lactobacillus johnsonii | Inhibits colonization of Helicobacter pylori |
| Miyauchi et al[36] | In vitro: Intestinal epithelial cells | L. rhamnosus OLL 2838 | Intestinal barrier activity |
| Bacterial lysates | |||
| Jensen et al[37] | In vivo in mice | Methylcoccus capsulatus | Enhance glucose regulation and decrease body and liver fat, MASLD |
| Mack et al[38] | Clinical trial | Escherichia coli DSM 17252 and Enterococcus faecalis DSM 16440 | Improves diarrhoea-predominant irritable bowel syndrome by ameliorating endotoxin translocation and indirectly prevents the gut-liver translocation |
| Osman et al[39] | In vivo: Male rats | L. paracasei | Reduced lipids and triglycerides accumulation and significant reduction in elevated liver enzymes |
| Wang et al[40] | In vivo: Male mice | L. rhamnosus GG | Alcoholic liver disease prevention |
| Compare et al[41] | Ex vivo: Organ culture model | Lactobacillus casei DG | Alleviate inflammatory effects in intestinal mucosa |
| Gao et al[8] | In vitro: Intestinal epithelial cells (Caco-2). In vivo: Mice | L. rhamnosus GG | Ameliorates intestinal barrier dysfunction and protects intestinal epithelium thereby preventing translocation to liver |
| Mi et al[42] | In vitro: RAW264.7 cells. In vivo: Male mice. Ex vivo: Mouse splenocytes | Bacillus velezensis Kh2-2 | Stimulate innate and adaptive immunity and regulate gut dysbiosis. Increase IL-2 secretion and inhibit IL-10 secretion in ex vivo model |
| Dinić et al[43] | In vitro study-HepG2 human hepatocyte cell line | Lactobacillus fermentum BGHV 110 | Stimulation of PTEN-induced putative kinase 1-dependent autophagy in HepG2 cells and mitigation of hepatotoxicity induced by acetaminophen |
| Bacterial vesicles | |||
| Hao et al[44] | In vivo mice | L. plantarum | Body weight loss and mitigate bleeding and colon shortening |
| Bacterial metabolites | |||
| He et al[45] | In vivo mice and in vitro in tumour cells | Short chain fatty acid-butyrate | Improve CD8+ T cell immunity providing anti-tumour effects |
| Suez and Elinav[46] | In vivo in mice | Phytate and inositol triphosphate | Enhance gut epithelial proliferation and injury recovery |
| Ma et al[47] | In vivo in mice | Indole | Activate PFKFB3 expression and inhibit macrophage activation, MASLD |
| Li et al[48] | In vivo in mice and in vitro bacterial culture | Isoallolithocolic acid | Regulation of Treg cells by bile acid metabolites |
| Dahech et al[49] | In vivo in male Wistar rats | Polysaccharides of Bacillus licheniformis | Reduce glucose levels and hepatic and renal toxicity measured through thiobarbituric acid reactive substances |
| Ghoneim et al[50] | In vivo in male Sprague-Dawlwy rats | Polysaccharides of Bacillus subtilis sp | Reduce glucose levels and prevent complications of diabetes |
| Amaretti et al[51] | In vitro | The mixture of Bifidobacterium, Lactobacillus, Lactococcus, and Streptococcus thermophilus | Anti-oxidant properties |
| Segawa et al[52] | In vitro | Polyphosphates of Lactobacillus brevis SBC8803 | Mediates epithelial barrier |
| Chen et al[53] | In vivo: Mice | SCFA of Clostridium butyricum sp | Regulate gut microbiome composition |
| Ticho et al[54] | In vivo in mice | Products of commensals after digestion of bile acids by Bacteroides, Eubacterium and Clostridium | Modulation via farsenoid-X receptor and GPCR5 which regulates lipid and lipoprotein metabolism |
| Rajakovich and Balskus[55] | In vivo | Products of Lactocilli, Bifidobacterium synthesize vitamins A, C, and B9 | Enhance mucous secretion by epithelial cells and maintain the integrity of goblet cells |
| Noronha et al[56] | In vivo | Products of Bacteroides and thetaiotaomicron enhance angiogenin 4 expression | Angiogenin 4 has antibacterial activities |
| Other components | |||
| Balaguer et al[57] | In vivo in Caenorhabditis elegans | Lipoteichoic acid of Bifidobacterium animalis subsp. Lactis CECT 8145 | Anti-obesity as it reduces fat in nematodes |
| Schiavi et al[58] | In vitro in human peripheral blood mononuclear cells | EPS of B. longum W11 | Regulates cytokine secretion and nuclear factor kappa B activation through anti-inflammatory properties |
| Bhat and Bajaj[16] | In vitro | EPS of L. paracasei M7 | Decrease total cholesterol, immunomodulation |
| Kim et al[59] | In vitro: Human monocyte cells (THP-1) | Lipoteichoic acid of L. plantarum | Inhibits pro-inflammatory signaling in THP-1 cells |
| Matsuguchi et al[60] | In vitro in RAW264.7 cells of mouse | Lipoteichoic acid of Lactobacillus acidophilus, Limosilactobacillus reuteri, L. plantarum | Attenuate LPS-induced tumor necrosis factor-alpha production |
| Wang et al[61] | In vivo in male mice | Lipoteichoic acid of L. paracasei D3-5 | Stimulate mucin production through its anti-inflammatory role and reduces systemic endotoxemia |
| Rahbar Saadat et al[62] | In vivo in mice | EPS of L. paracasei | Exhibits cholesterol lowering and metabolic regulation properties |
| Kareem et al[63] | In vitro | Cell free supernatant of L. plantarum RG11, RG14, RI11, UL4, TL1, RS5 | Antimicrobial activity |
| Bali et al[64] | In vitro | Cell-free supernatant Bifidobacterium sp | Bacteriocin production against pathogenic organisms |
| Foo et al[65] | In vivo in mice | L. plantarum I-UL4, Bacteriocin | Significant reduction in total cholesterol concentrations in comparison to controls |
| Riaz Rajoka et al[66] | In vitro | Cell-free supernatant of L. rhamnosus SHA111, SHA112, and SHA113 | Induces apoptosis by up-regulation of BAD, BAX, Caspase-3, Caspase-8, Caspase-9, and down regulation of BCL-2 genes |
| Qi et al[67] | In vitro in RAW264.7 cells of mouse macrophages | Cell wall components of L. rhamnosus GG | Components protect macrophages from LPS-induced inflammation |
- Citation: Jeyaraman N, Jeyaraman M, Mariappan T, Nallakumarasamy A, Subramanian P, T P, Vetrivel VN. Harnessing postbiotics for liver health: Emerging perspectives. World J Gastrointest Pharmacol Ther 2025; 16(4): 109177
- URL: https://www.wjgnet.com/2150-5349/full/v16/i4/109177.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v16.i4.109177
